InSysBio announces its participation in ChinaBio Partnering Forum 2026 which is to be held from April 28–29, 2026 in Shanghai, China. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #B302 and a poster at the Antibody & ADC Summit:

Tuesday, April 28:

• "Optimization of step-up dosing regimen of T-cell engagers to mitigate cytokine release syndrome using quantitative systems pharmacology modeling: tarlatamab case study" by Oleg Demin Jr, Galina Saynukova, Dmitry Shchelokov

Check out our poster and Booth #B302!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share